Nyxoah SA (NYXH) Stock Forecast & Price Target
Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Nyxoah SA (NYXH), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Nyxoah SA, analysts forecast revenue rising from EUR 10.30M in 2025 to EUR 271.38M in 2030; the average estimate for 2030 earnings per share is EUR 0.03; with published estimates ranging from EUR 0.03 to EUR 0.04; 5 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (EUR)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast (EUR)
Nyxoah SA (NYXH) forecast — frequently asked questions
What is the analyst price target for Nyxoah SA?
Analysts covering Nyxoah SA (NYXH) have a consensus price target of $3.08, 250.0% above the current price of $0.88. Published targets range from $2.31 to $4.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Nyxoah SA's earnings?
The average analyst estimate for Nyxoah SA (NYXH) earnings per share in 2030 is 0.03, with individual estimates between 0.03 and 0.04.
How much revenue is Nyxoah SA expected to make?
Analysts forecast Nyxoah SA (NYXH) revenue of EUR 271.38M in 2030, based on 2 published estimates.
How many analysts cover NYXH?
5 analysts contribute estimates for Nyxoah SA (NYXH). Thin coverage makes an average less reliable.
Analyst forecasts for other Medical - Specialties stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.